Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.
until further notice
SourceEuropean Child & Adolescent Psychiatry, 15, 8, (2006), pp. 476-495
Article / Letter to editor
Display more detailsDisplay less details
European Child & Adolescent Psychiatry
SubjectDCN 1: Perception and Action; DCN 3: Neuroinformatics; EBP 1: Determinants in Health and Disease; NCEBP 9: Mental health; UMCN 3.2: Cognitive neurosciences
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.
Upload full text
Use your RU credentials (u/z-number and password) tolog in with SURFconextto upload a file for processing by the repository team.